EX-99.1 2 pressreleaseq223final.htm EX-99.1 Document

EXHIBIT 99.1
image_0a.jpg
Flotek Reports Second Quarter 2023 Results Highlighted by
108% Sequential Growth in Gross Profit

HOUSTON - August 8, 2023 - Flotek Industries, Inc. (“Flotek” or the “Company”) (NYSE: FTK) today announced significantly improved operational and financial results for the second quarter ended June 30, 2023. The second quarter results further build upon the Company’s turn-around momentum as nearly all financial metrics showed strong sequential growth.

Financial Summary
(in thousands)Q2 2023Q2 2022
Percent Change
Q1 2023
Percent Change
Total Revenues$50,594$29,37372%$48,0075%
Gross Profit (Loss)$3,904$(2,305)269%$1,880108%
Adjusted Gross Profit (Loss) (1)
$5,091$(1,578)423%$2,64792%
Net Income (Loss)$(21)$6,240NM$21,343NM
Adjusted EBITDA (1)
$(2,004)$(7,242)72%$(3,851)48%

(1)A non-GAAP financial measure. See the “Unaudited Reconciliation of Non-GAAP Items and Non-Cash Items Impacting Earnings” section in this release for more information, including reconciliations to the most comparable GAAP measures.

Second Quarter 2023 Highlights
    
Reported gross profit of $3.9 million and adjusted gross profit(1) of $5.1 million marking the second consecutive quarter of positive results in both metrics. Second quarter of 2023 gross profit and adjusted gross profit(1) increased 108% and 92%, respectively, as compared to first quarter of 2023 results. Gross profit margin and adjusted gross profit margin(1) for the second quarter of 2023 increased to 8% and 10%, respectively.
Achieved strong growth in total revenues of 72% from the second quarter of 2022, resulting from Flotek’s strategic 10-year supply agreement with ProFrac Holdings, LLC (“ProFrac”). Second quarter of 2023 total revenues increased 5% sequentially despite an industry-wide slowdown in upstream activity and benefited from a 68% increase in transactional (non-ProFrac) chemistry business compared to the first quarter of 2023.
Improved adjusted EBITDA(1) for the eighth consecutive quarter reporting a 48% sequential increase.
Appointed Dr. Ryan Ezell to the role of Chief Executive Officer to lead Flotek into its next phase of profitable growth.
Appointed Mr. Harsha V. Agadi to the role of Chairman of the Board of Flotek.

(1)A non-GAAP financial measure. See the “Unaudited Reconciliation of Non-GAAP Items and Non-Cash Items Impacting Earnings” section in this release for more information, including reconciliations to the most comparable GAAP measures.

1



August 2023 Update
    
Reiterate full year 2023 guidance for total revenues of $210 million to $230 million and an adjusted gross profit margin of 8% to 10%.
Report considerable progress toward securing an asset-based loan (“ABL”). See balance sheet and liquidity discussion below.

Management Commentary

Chief Executive Officer Ryan Ezell commented, “Our second quarter results highlight our operational excellence and the rapid improvement in Flotek’s business fundamentals as we execute our corporate strategy. Our cost control initiatives continue to enhance profitability as demonstrated by adjusted gross profit nearly doubling from the first quarter with the associated margin increasing to 10%. Accordingly, we have high confidence in adjusted EBITDA turning positive before year-end.
“Operationally, even as the industry experienced less well stimulation activity during the quarter, our differentiated chemistry solutions, highlighted by the performance of our transactional chemistry business, enabled us to grow revenues and margins. Looking ahead, we are well positioned with a strong balance sheet that will be enhanced by the credit facility that we are actively pursuing. This will augment our liquidity and support our growth and path to sustained profitability.”   
Second Quarter 2023 Financial Results
Revenue: Flotek reported total revenues of $50.6 million for the second quarter of 2023, which was an increase of 72% compared to total revenues of $29.4 million for the second quarter of 2022 and a 5% increase compared to total revenues of $48.0 million for the first quarter of 2023. Second quarter of 2023 revenues benefited from a 68% sequential increase in transactional chemistry revenue.

Gross Profit (Loss): The Company generated gross profit of $3.9 million as compared to a gross loss of $2.3 million for the second quarter of 2022 and gross profit of $1.9 million for the first quarter of 2023. The improvement in second quarter of 2023 gross profit was the result of the increase in transactional chemistry revenue during the quarter and continuing initiatives to drive further cost improvements with respect to freight logistics and materials.

Adjusted Gross Profit (Loss) (Non-GAAP)(1): Flotek generated adjusted gross profit of $5.1 million during the second quarter of 2023 compared to adjusted gross loss of $1.6 million for the second quarter of 2022 and gross profit of $2.6 million for the first quarter of 2023. Adjusted gross profit (loss) primarily excludes non-cash items, including amortization of contract assets, which reduces both revenue and gross profit.

Selling, General and Administrative (“SG&A”) Expense: SG&A expense totaled $8.4 million for the second quarter of 2023 compared to $6.8 million for the second quarter of 2022 and $6.5 million for the first quarter of 2023. Second quarter of 2023 SG&A included legal costs incurred in connection with the settlement of a portion of ongoing legacy litigation, as well as the final costs associated with the CEO transition. SG&A during the first quarter of 2023 included a $1.1 million credit to stock compensation
2



expense related to head-count reductions. Excluding non-cash stock compensation, second quarter SG&A increased $0.5 million sequentially.
Severance Costs: Flotek recorded a $2.3 million credit to severance expenses during the second quarter of 2023 in connection with the settlement of a portion of ongoing legacy litigation. The Company had accrued certain severance payments in connection with this litigation in prior years and reversed the accrual during the second quarter after reaching the settlement.

Net Income (Loss) and EPS: Flotek reported a net loss of $21 thousand, or $0 per basic share, for the second quarter of 2023. This compares to net income of $6.2 million, or $0.08 per basic share, for the second quarter of 2022 and net income of $21.3 million, or $0.22 per basic share, in the first quarter of 2023. Net income/(loss) during the second quarter of 2023 and 2022 and the first quarter of 2023 included non-cash gains on the fair value measurement of convertible notes totaling $3.9 million, $17.2 million, and $26.1 million, respectively.

Adjusted EBITDA (Non-GAAP)(1): Adjusted EBITDA was negative $2.0 million in the second quarter of 2023 as compared to negative $7.2 million in the second quarter of 2022 and negative $3.9 million in the first quarter of 2023. Adjusted EBITDA continues to trend upward and the Company expects to report positive adjusted EBITDA during 2023.

(1)See the “Unaudited Reconciliation of Non-GAAP Items and Non-Cash Items Impacting Earnings” section in this release for more information, including reconciliations to the most comparable GAAP measures.

Balance Sheet and Liquidity

Flotek has received credit approval from a prospective lender in connection with a proposed ABL. The Company is reviewing the loan documents as well as completing final administrative matters prior to closing. The proposed ABL would provide credit availability based upon eligible accounts receivable, inventory and real estate values. The Company expects to provide an update before the end of August 2023.

Cash and cash equivalents were $8.8 million as of June 30, 2023, compared to $12.4 million as of March 31, 2023. Cash and cash equivalents were used during the quarter for working capital purposes.

Conference Call Details

Flotek will host a conference call on August 9, 2023, at 9:00 a.m. CDT (10:00 a.m. EDT) to discuss its second quarter 2023 results. Participants may access the call through Flotek’s website at www.flotekind.com under “Webcasts’’ or by telephone toll free at 1-844-835-9986 (international toll: 1-412-317-5270) approximately five minutes prior to the start of the call. Following the conclusion of the conference call, a recording of the call will be available on the Company’s website.

Upcoming Investor Event
Members of the Company’s management are scheduled to participate in EnerCom Denver – The Energy Investment Conference to be held in Denver, Colorado, August 14-16, 2023. Ryan Ezell, Chief Executive Officer of Flotek, will present on August 15, 2023, at 8:50 a.m. MT and
3



will be joined by Bond Clement, Chief Financial Officer, in hosting meetings with investors throughout the day. Dr. Ezell will also participate in a service industry panel discussion on August 16 at 9:50 a.m. MT. A live webcast of the events will be available on the conference website at www.enercomdenver.com. Presentation slides will be posted on the Investor Relations section of Flotek’s corporate website at www.flotekind.com prior to the start of the presentation.

About Flotek Industries, Inc.

Flotek Industries, Inc. is an advanced technology-driven, green chemical and data analytics company providing unique and innovative completion solutions that have a proven, positive impact on sustainability and reducing the overall environmental impact of energy on air, land, water and people. Flotek has an intellectual property portfolio of over 170 patents and a global presence in more than 15 countries throughout North America, Latin America, the Middle East and North Africa. Flotek has established collaborative partnerships focused on sustainable and optimized chemistry and data solutions which improve well performance and allow its customers to generate higher returns on invested capital.

Flotek is based in Houston, Texas and its common shares are traded on the New York Stock Exchange under the ticker symbol “FTK”. For additional information, please visit www.flotekind.com.

Forward-Looking Statements

Certain statements set forth in this press release constitute forward-looking statements (within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934) regarding Flotek Industries, Inc.’s business, financial condition, results of operations and prospects. Words such as will, continue, expects, anticipates, intends, plans, believes, seeks, estimates and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements in this press release. Although forward-looking statements in this press release reflect the good faith judgment of management, such statements can only be based on facts and factors currently known to management. Consequently, forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from the results and outcomes discussed in the forward-looking statements. Further information about the risks and uncertainties that may impact the company are set forth in the Company’s most recent filing with the Securities and Exchange Commission on Form 10-K (including, without limitation, in the “Risk Factors” section thereof), and in the Company’s other SEC filings and publicly available documents. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this press release.


Company Contact

Bond Clement
Chief Financial Officer
E: ir@flotekind.com
P: (713) 726-5322
4



FLOTEK INDUSTRIES, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
 Three Months EndedSix Months Ended
 6/30/20236/30/20223/31/20236/30/20236/30/2022
Revenue:
Revenue from external customers
$    17,820$    12,824$    11,652$    29,472$    23,206
Revenue from related party32,77416,54936,35569,13019,046
Total revenues50,59429,37348,00798,60242,252
Cost of goods sold46,69031,67846,12792,81745,036
Gross profit (loss)3,904(2,305)1,8805,785(2,784)
Operating costs and expenses:
Selling, general, and administrative8,3516,8216,45114,80311,707
Depreciation174182176349377
Research and development8601,1156141,4742,530
Severance costs(2,279)6102,223(56)603
Gain on sale of property and equipment(1,914)(1,906)
Gain on lease termination(584)
Gain in fair value of Contract Consideration Convertible Notes Payable(3,874)(17,158)(26,095)(29,969)(13,266)
Total operating costs and expenses3,232(10,344)(16,631)(13,399)(539)
Income (loss) from operations6728,03918,51119,184(2,245)
Other income (expense):
Paycheck protection plan loan forgiveness4,5224,522
Interest expense(705)(1,597)(1,672)(2,377)(2,265)
Other income (expense) , net19(104)(9)9120
Total other income (expense), net(686)(1,701)2,8412,154(2,145)
Income (loss) before income taxes(14)6,33821,35221,338(4,390)
Income tax expense(7)(98)(9)(16)(94)
Net income (loss)$    (21)$    6,240$    21,343$    21,322$    (4,484)
Income (loss) per common share:
Basic$    —$    0.08$    0.22$    0.18$    (0.06)
Diluted$    (0.02)$    (0.05)$    (0.02)$    (0.04)$    (0.12)
Weighted average common shares:
Weighted average common shares used in computing basic income (loss) per common share
143,43374,86198,808121,24473,476
Weighted average common shares used in computing diluted loss per common share
169,500124,335158,441164,165107,086





5



FLOTEK INDUSTRIES, INC.UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
June 30, 2023December 31, 2022
ASSETS
Current assets:
Cash and cash equivalents$    8,841$    12,290
Restricted cash101100
Accounts receivable, net of allowance for credit losses of $682 and $623 at June 30, 2023 and December 31, 2022, respectively16,85519,136
Accounts receivable, related party, net of allowance for credit losses of $0 at June 30, 2023 and December 31, 2022, respectively23,03322,683
Inventories, net18,39715,720
Other current assets4,0514,045
Current contract asset7,7167,113
Total current assets78,99481,087
Long-term contract assets69,58372,576
Property and equipment, net4,7534,826
Operating lease right-of-use assets4,2795,900
Deferred tax assets, net404404
Other long-term assets1717
TOTAL ASSETS$    158,030$    164,810
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable$    44,949$    33,375
Accrued liabilities5,1788,984
Income taxes payable1297
Interest payable130
Current portion of operating lease liabilities2,9023,328
Current portion of finance lease liabilities3736
Current portion of long-term debt1792,052
Convertible notes payable19,799
Contract Consideration Convertible Notes Payable83,570
Total current liabilities53,257151,371
Deferred revenue, long-term3544
Long-term operating lease liabilities6,5848,044
Long-term finance lease liabilities319
Long-term debt1492,736
TOTAL LIABILITIES60,028162,214
Stockholders’ equity:
Common stock, $0.0001 par value, 240,000,000 shares authorized; 158,220,075 shares issued and 151,541,446 shares outstanding at June 30, 2023; 83,915,918 shares issued and 77,788,391 shares outstanding at December 31, 2022
158
Additional paid-in capital462,517388,177
Accumulated other comprehensive income147181
Accumulated deficit(330,197)(351,519)
Treasury stock, at cost; 6,678,629 and 6,127,527 shares at June 30, 2023 and December 31, 2022, respectively
(34,480)(34,251)
Total stockholders’ equity98,0022,596
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$    158,030$    164,810

6



FLOTEK INDUSTRIES, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)

7



 Six months ended June 30,
 20232022
Cash flows from operating activities:
Net income (loss)$    21,322$    (4,484)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Change in fair value of contingent consideration
(324)(134)
Change in fair value of Contract Consideration Convertible Notes Payable
(29,969)(13,266)
Amortization of convertible note issuance costs
83414
Payment-in-kind interest expense
2,2841,819
Amortization of contract assets
2,390737
Depreciation and amortization
349377
Provision for credit losses, net of recoveries
6387
Provision for excess and obsolete inventory
497769
Gain on sale of property and equipment
(1,906)
Gain on lease termination
(584)
Non-cash lease expense
1,621112
Stock compensation expense
(836)1,591
Deferred income tax (benefit) expense
(5)
Paycheck protection plan loan forgiveness
(4,522)
Changes in current assets and liabilities:
Accounts receivable
2,218(21,741)
Accounts receivable, related party
(350)11,600
Inventories
(3,158)(4,521)
Income taxes receivable
7
Other assets
(6)(232)
Contract assets, net
(3,600)
Accounts payable
11,57412,154
Accrued liabilities
(3,491)(2,924)
Operating lease liabilities
(1,886)(308)
Income taxes payable
(85)99
Interest payable
(8)24
Net cash used in operating activities(2,234)(23,915)
Cash flows from investing activities:
Capital expenditures(292)(5)
Proceeds from sale of assets4,194
Net cash (used in) provided by investing activities(292)4,189
Cash flows from financing activities:
Payment for forfeited stock options(617)
Payments on long term debt(60)
Proceeds from issuance of convertible notes21,150
Payment of issuance costs of convertible notes(1,084)
Proceeds from issuance of warrants19,500
Payments to tax authorities for shares withheld from employees(229)(138)
Proceeds from issuance of stock3324
Payments for finance leases(15)(21)
Net cash (used in) provided by financing activities(888)39,431
Effect of changes in exchange rates on cash and cash equivalents(34)95
Net change in cash and cash equivalents and restricted cash(3,448)19,800
Cash and cash equivalents at the beginning of period
12,29011,534
Restricted cash at the beginning of period
1001,790
Cash and cash equivalents and restricted cash at beginning of period12,39013,324
Cash and cash equivalents at end of period
8,84133,084
Restricted cash at the end of period
10140
Cash and cash equivalents and restricted cash at end of period$    8,942$    33,124


8




FLOTEK INDUSTRIES, INC.
UNAUDITED RECONCILIATION OF NON-GAAP ITEMS AND NON-CASH ITEMS IMPACTING EARNINGS
(in thousands)
 Three Months EndedSix Months Ended
 6/30/20236/30/20223/31/20236/30/20236/30/2022
Gross profit (loss)$    3,904$    (2,305)$    1,880$    5,785$    (2,784)
Stock compensation expense2218(139)$    (137)$    374
Severance and retirement1115$    26$    3
Contingent liability revaluation35(228)(359)$    (324)$    (134)
Amortization of contract assets1,1397371,250$    2,389$    737
Adjusted Gross profit (loss)$    5,091$    (1,578)$    2,647$    7,739$    (1,804)
Net income (loss)$    (21)$    6,240$    21,343$    21,322$    (4,484)
Interest expense7051,5971,6722,3772,265
Income tax expense79891694
Depreciation and amortization174182176349377
EBITDA (Non-GAAP)$    865$    8,117$    23,200$    24,064$    (1,748)
Stock compensation expense274852(1,112)(838)1,591
Severance and retirement(2,268)6102,238(30)606
Contingent liability revaluation35(228)(359)(324)(134)
Gain on disposal of assets(1,914)(1,906)
Gain on lease termination(584)
Contract Consideration Convertible Notes Payable revaluation adjustment(3,874)(17,158)(26,095)(29,969)(13,266)
Amortization of contract assets1,1397371,2502,389737
PPP loan forgiveness(4,522)(4,522)
Non-Recurring professional fees1,8251,7421,5493,3762,017
Adjusted EBITDA (Non-GAAP)$    (2,004)$    (7,242)$    (3,851)$    (5,854)$    (12,687)

(1) Management believes that adjusted gross profit and adjusted EBITDA for the three and six months ended June 30, 2023, and 2022, and the three months ended March 31, 2023, are useful to investors to assess and understand operating performance, especially when comparing those results with previous and subsequent periods. Management views the expenses noted above to be outside of the Company’s normal operating results. Management analyses operating results without the impact of the above items as an indicator of performance, to identify underlying trends in the business and cash flow from continuing operations, and to establish operational goals.


9